Thomas DiRaimondo
CIK: 0002005618
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Janux Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jan 2, 2026JANX
Janux Therapeutics, Inc.
Sale(S)Direct2.5K shares at avg. $13.73$34K - Jan 2, 2026JANX
Janux Therapeutics, Inc.
Award(A)Direct31.4K shares- - Jan 2, 2025JANX
Janux Therapeutics, Inc.
Award(A)Direct24K shares- - Sep 27, 2024JANX
Janux Therapeutics, Inc.
Sale(S)Direct4.3K shares at avg. $46.21$200K - Sep 27, 2024JANX
Janux Therapeutics, Inc.
Sale(S)Direct675 shares at avg. $47.22$32K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | Sale(S) | 2,505 | $13.73 | $34,394 | Direct |
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | Award(A) | 31,400 | - | $0 | Direct |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | Award(A) | 24,000 | - | $0 | Direct |
| Sep 27, 2024 | JANX Janux Therapeutics, Inc. | Sale(S) | 4,325 | $46.21 | $199,840 | Direct |
| Sep 27, 2024 | JANX Janux Therapeutics, Inc. | Sale(S) | 675 | $47.22 | $31,877 | Direct |
1-5 of 5 transactions
About DiRaimondo Thomas
DiRaimondo Thomas (SEC CIK 0002005618) files insider reports with the SEC as Chief Scientific Officer of Janux Therapeutics, Inc. (JANX).
Signal8 holds 3 ownership filings by DiRaimondo Thomas, all Form 4s, filed between Sep 27, 2024 and Jan 2, 2026. Those filings report 5 transactions, from Sep 27, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DiRaimondo Thomas's filings is in SAN DIEGO, CA.
Recent filings by DiRaimondo Thomas
Other insiders filing for Janux Therapeutics, Inc. (JANX)
- Campbell David Alan, President and CEO
- RA CAPITAL MANAGEMENT, L.P., Director
- Simson Jake, Director
- Kung Winston, Director
- Hernday Natasha, Director
- DOBMEIER ERIC, Director